| |
[摘要]：The lack of effective therapies for metastatic prostate cancer and the toxicity profiles of current prostate cancer therapies have created the need for continued development of immunogenic treatments with a favorable toxicity profile. Immune-based strategies target specific cancer antigens to help create a more personalized approach to achieve cancer control without significant toxicity. A variety of antigen-specific cancer vaccine trials of different phases have been conducted. Although the underlying mechanisms behind each vaccine vary, all immunogenic approaches have the same goal of eliciting a prostate tumor-associated antigen response. Currently, only one vaccine has been approved by the FDA; however, further developments may lead to the approval of more vaccines in the near future. This review provides an overview of vaccine-based strategies with details about their underlying mechanisms and relevant clinical trial data. |
|
